Penicillamine and Schizophrenia—A Clinical Trial

1969 ◽  
Vol 115 (519) ◽  
pp. 173-176 ◽  
Author(s):  
J. W. Affleck ◽  
A. J. Cooper ◽  
A. D. Forrest ◽  
J. R. Smythies ◽  
A. K. Zealley
Keyword(s):  
Clinical Trial ◽  
Autoimmune Disorder ◽  
Normal Diet ◽  
Double Blind Trial ◽  
Chronic Patients ◽  
Double Blind ◽  
Blind Trial ◽  
Schizophrenic Patients ◽  
Biochemical Lesion ◽  
One Year

One specific hypothesis concerning the biochemical lesion in schizophrenia was put forward by McIsaac (1961) on the basis of the close chemical relationship between the pineal hormone melatonin and the hallucinogenic drug harmine. On this basis Nicholson et al. (1966) conducted a clinical trial of D-penicillamine plus a low copper diet in schizophrenics, with encouraging results. They used 1,200 mg. daily in a double-blind trial against placebo for six weeks. Hollister et al. (1966) also treated schizophrenic patients with D-penicillamine, but for a different reason—they suggested that depolymerization might be effective if schizophrenia is an autoimmune disorder. They used doses of 1,000 mg. daily for five weeks following an initial build up, and noted no clinical amelioration in 13 schizophrenics studied. A normal diet was given. Walshe (1967) failed to find any improvement in 4 chronic patients on penicillamine for one year.

A Double-Blind Trial of Budesonide Ointment and Betamethasone-17-Valerate Ointment in Psoriasis

1981 ◽  
Vol 9 (3) ◽  
pp. 236-238 ◽  
Author(s):  
H Schmidt ◽  
N Hjorth ◽  
L Salde
Keyword(s):  
Clinical Trial ◽  
Maintenance Treatment ◽  
Double Blind Trial ◽  
Double Blind ◽  
Residual Symptoms ◽  
Blind Trial

In a double-blind within-patient clinical trial in psoriasis, budesonide 0.025% ointment has been shown to be at least as efficient as betamethasone 17-valerate 0.1% ointment. A lower concentration of budesonide ointment, 0.01%, was used for 4 weeks of maintenance treatment. This concentration controlled residual symptoms well in a majority of the patients, thirty-two in number.

A Double-Blind Clinical Trial of a New Benzodiazepine, Flunitrazepam, as a Hypnotic Agent

1974 ◽  
Vol 2 (5) ◽  
pp. 370-373 ◽  
Author(s):  
R Piret ◽  
J C Devoghel
Keyword(s):  
Clinical Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Double Blind Clinical Trial ◽  
Hypnotic Agent

Flunitrazepam 3 mg and 5 mg, phenobarbitone 200 mg and placebo were compared as pre-operative hypnotic agents in a double-blind trial. Two hundred and seventy-three patients were included in the study. The lower dose 3 mg of flunitrazepam was shown to be superior to the higher dose 5 mg and to phenobarbitone 200 mg and placebo.

A Double-blind Trial of Oxypertine for Anxiety Neurosis

1965 ◽  
Vol 111 (475) ◽  
pp. 527-529 ◽  
Author(s):  
J. T. Robinson ◽  
L. S. Davies ◽  
Norman Kreitman ◽  
J. B. Knowles
Keyword(s):  
Clinical Trial ◽  
Chronic Schizophrenia ◽  
Anxiety Symptoms ◽  
Anxiety Scale ◽  
Adjunctive Treatment ◽  
Double Blind Trial ◽  
Anxiety Neurosis ◽  
Double Blind ◽  
Blind Trial ◽  
Chronic Anxiety

Oxypertine is a new piperazine derivative, believed to have tranquillizing, antiadrenergic and hypotensive properties. Unpublished reports have suggested that it might be useful in chronic schizophrenia, although the recent study by Calwell et al. (1964) shows that its usefulness in this condition is limited. In view of its putative tranquillizing effect, the present clinical trial was undertaken to determine, under double-blind conditions, its efficacy as an adjunctive treatment for chronic anxiety neurosis. Ratings of anxiety symptoms were the major criteria for assessing the patients' progress, but the IPAT Anxiety Scale (Cattell and Scheier, 1957) was also included as a potentially useful measure of anxiety. An investigation of its validity was a subsidiary aim of the study.

Activity in chronic schizophrenic patients: comparison of pimozide with fluphenazine in a double blind trial

1975 ◽  
Vol 5 (2) ◽  
pp. 161-164 ◽  
Author(s):  
A. C. P. Sims ◽  
I. G. Burnside
Keyword(s):  
Operant Conditioning ◽  
Crossover Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Chronic Schizophrenic ◽  
Free Operant ◽  
Significant Difference ◽  
Schizophrenic Patients ◽  
Psychiatric Rating

SynopsisA double-blind crossover trial was carried out comparing pimozide with fluphenazine. The effects of the drugs on the activity of 20 chronic inert male schizophrenic patients were measured using nursing observations, psychiatric rating, and an operant conditioning method. When activity was assessed in these different ways, no significant difference was found between the two drugs on any of the measures. It is concluded that pimozide does not effectively increase the activity in such patients. It is considered that the free operant conditioning method used was shown to be a useful measure for comparing therapy in chronic schizophrenic patients.

Sign in / Sign up

Export Citation Format

Share Document